EIF4A3 and hepatocellular carcinoma: A significant number of these splicing events were validated in vitro using EIF4A3‐silenced HepG2 cells, which showed that the splicing pattern of some of these relevant genes (ACIN1, ASLX1, CD5KRAP3 or PYGL) was altered after EIF4A3‐silencing (Figure S4A,B), confirming the implication of EIF4A3 in the splicing of crucial genes in HCC pathophysiology.